<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246879</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00103163</org_study_id>
    <nct_id>NCT04246879</nct_id>
  </id_info>
  <brief_title>MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases</brief_title>
  <official_title>Diagnostic Accuracy of Delayed MRI Contrast Enhancement Characteristics and Radiation Necrosis Following Stereotactic Radiosurgery (SRS) for Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether an additional magnetic resonance image (MRI)
      sequence can improve the ability to distinguish radiation damage from tumor recurrence in
      participants with brain metastasis who have previously been treated with stereotactic
      radiosurgery (SRS).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of positive MRI sequences along with positive tumor biopsies</measure>
    <time_frame>baseline</time_frame>
    <description>true tumor will be detected by delayed MRI as determined by biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of negative MRI sequences along with negative tumor biopsies</measure>
    <time_frame>baseline</time_frame>
    <description>absence of tumor will be detected by delayed MRI as determined by biopsy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Subjects undergo one additional delayed MRI sequence</description>
    <arm_group_label>MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, age â‰¥18

          -  Metastatic malignancy with at least 1 brain metastasis previously treated with SRS

          -  Patients may have also received whole brain radiation therapy (WBRT) for management of
             brain metastatic disease but this is not required for study participation

          -  Patients must have been diagnosed with a metastatic solid tumor of any histological
             type except small cell lung cancer (SCLC), or lymphoma.

          -  Radiographic progression on post-SRS imaging at previously treated SRS site(s)

          -  Must be a candidate for LITT procedure as determined by treating neurosurgeon and/or
             anesthesia team

          -  Patients must sign study-specific informed consent prior to study entry

        Exclusion Criteria:

          -  Poor surgical candidate as determined by treating neurosurgeon and/or anesthesia team

          -  Unable to undergo contrasted MRI (e.g. incompatible medical device, inadequate renal
             function per standard institutional clinical protocol, contrast allergy)

          -  Small cell lung cancer (SCLC) or lymphoma histology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Floyd, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Mewshaw, MS NP</last_name>
    <phone>919 668 5211</phone>
    <email>jennifer.mewshaw@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eileen Duffy, BNS OCN CCRP</last_name>
      <phone>919-668-3726</phone>
    </contact>
    <investigator>
      <last_name>Scott Floyd, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Laser Interstitial Thermal Therapy (LITT)</keyword>
  <keyword>Stereotactic radiosurgery (SRS)</keyword>
  <keyword>Magnetic resonance image (MRI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

